Goodwin: Abingworth to Provide Gilead Sciences Up to $210M in Funding
March 06, 2024
March 06, 2024
BOSTON, Massachusetts, March 6 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised Abingworth (NASDAQ: CG) on its strategic development financing agreement with Gilead Sciences. The financing agreement will provide up to $210 million in funding to support select clinical studies of Trodelvy(R) (sacituzumab govitecan-hziy), within non-small cell lung cancer. As part of the agreement, Launch Therapeutics, a clinical development company backed by A . . .
The Life Sciences team advised Abingworth (NASDAQ: CG) on its strategic development financing agreement with Gilead Sciences. The financing agreement will provide up to $210 million in funding to support select clinical studies of Trodelvy(R) (sacituzumab govitecan-hziy), within non-small cell lung cancer. As part of the agreement, Launch Therapeutics, a clinical development company backed by A . . .